Quantcast

Altimmune closer to phase 2 trials for hepatitis B drug

A Gaithersburg biotechnology company working on a hepatitis B drug said it came out of a recent meeting with the FDA a step closer to conducting a planned clinical trial for the drug.

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

*